Nektar Therapeutics (NASDAQ:NKTR) Given Consensus Rating of “Hold” by Analysts

Shares of Nektar Therapeutics (NASDAQ:NKTR) have been given an average recommendation of “Hold” by the six analysts that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $3.00.

Separately, Rodman & Renshaw initiated coverage on Nektar Therapeutics in a research note on Friday, June 28th. They issued a “buy” rating and a $2.00 price objective for the company.

Insider Activity

In other Nektar Therapeutics news, major shareholder Deep Track Capital, Lp sold 56,000 shares of the stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $1.78, for a total transaction of $99,680.00. Following the completion of the sale, the insider now owns 18,344,000 shares of the company’s stock, valued at approximately $32,652,320. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Nektar Therapeutics news, major shareholder Deep Track Capital, Lp sold 56,000 shares of the stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $1.78, for a total transaction of $99,680.00. Following the completion of the sale, the insider now owns 18,344,000 shares of the company’s stock, valued at approximately $32,652,320. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Howard W. Robin sold 16,650 shares of the stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average price of $1.75, for a total transaction of $29,137.50. Following the sale, the chief executive officer now directly owns 863,239 shares of the company’s stock, valued at approximately $1,510,668.25. The disclosure for this sale can be found here. Insiders sold 99,505 shares of company stock valued at $165,089 over the last quarter. 3.71% of the stock is owned by company insiders.

Hedge Funds Weigh In On Nektar Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. SG Americas Securities LLC boosted its holdings in shares of Nektar Therapeutics by 30.6% during the 4th quarter. SG Americas Securities LLC now owns 101,687 shares of the biopharmaceutical company’s stock worth $57,000 after buying an additional 23,829 shares in the last quarter. Marquette Asset Management LLC boosted its holdings in shares of Nektar Therapeutics by 25.5% during the 4th quarter. Marquette Asset Management LLC now owns 186,163 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 37,785 shares in the last quarter. Values First Advisors Inc. bought a new position in shares of Nektar Therapeutics during the 2nd quarter worth approximately $56,000. State Board of Administration of Florida Retirement System bought a new position in shares of Nektar Therapeutics during the 1st quarter worth approximately $63,000. Finally, Citigroup Inc. boosted its holdings in shares of Nektar Therapeutics by 1,993.9% during the 3rd quarter. Citigroup Inc. now owns 77,978 shares of the biopharmaceutical company’s stock worth $46,000 after buying an additional 74,254 shares in the last quarter. 75.88% of the stock is currently owned by institutional investors.

Nektar Therapeutics Trading Up 0.7 %

Shares of NASDAQ NKTR opened at $1.38 on Tuesday. The company has a market cap of $253.95 million, a price-to-earnings ratio of -1.50 and a beta of 0.66. Nektar Therapeutics has a 12 month low of $0.41 and a 12 month high of $1.93. The stock has a 50-day moving average price of $1.34 and a two-hundred day moving average price of $1.12.

Nektar Therapeutics (NASDAQ:NKTR) last issued its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.03. The firm had revenue of $21.64 million during the quarter, compared to the consensus estimate of $14.91 million. Nektar Therapeutics had a negative return on equity of 107.31% and a negative net margin of 195.02%. During the same quarter in the previous year, the firm earned ($0.25) earnings per share. On average, sell-side analysts predict that Nektar Therapeutics will post -0.84 earnings per share for the current year.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.